证券代码：605199 证券简称：葫芦娃 公告编号：2025-040

Group 1 - The company has received approval from the National Medical Products Administration for the clinical trial of "Lung Heat Cough and Asthma Granules" [1][2] - The drug is an improved version of the already marketed "Pediatric Lung Heat Cough and Asthma Granules," now targeting adults and including additional indications for influenza [2] - The drug is classified as a Type 2.3 modified traditional Chinese medicine, suitable for treating symptoms related to heat toxin attacking the lungs [2] Group 2 - After obtaining the clinical trial approval, the drug must undergo clinical trials and receive further evaluation from the National Medical Products Administration before it can be produced and marketed [3]